1. NEW ORLEANS ERNEST N. MORIAL CONVENTION CENTER NEW ORLEANS,
LOUISIANA MAY 24-27 3URJUDP %RRN 17 WWW.MSCARE.ORG/2017 ANNUAL
MEETING OF THE CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS
2. Available for iPhone , iPad , and Android Supported by
Download the 2017 CMSC Annual Meeting Mobile App Search for CMSC
2017
3. 2017 ANNUAL MEETING New Orleans, Louisiana New Orleans
Ernest N. Morial Convention Center May 24 - 27 IN COLLABORATION
WITH
4. 52017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 2017 Annual Meeting of
the Consortium of Multiple Sclerosis Centers May 24-27 U New
Orleans, Louisiana A Message from the President
..............................................................................7
Welcome from the CMSC Administrative
Ofce....................................................8
Conference Target Audience and Learning Track Objectives
...............................9 Accreditation and
Designation.............................................................................10
Meeting Space Floor Plan - Ernest N . Morial Convention
Center.....................11 Day 1:
Wednesday................................................................................................13
Day 2: Thursday
...................................................................................................17
Day 3: Friday
........................................................................................................22
Day 4:
Saturday....................................................................................................27
Program Grid
.......................................................................................................29
Session Descriptions
...........................................................................................33
Distinguished Faculty
..........................................................................................45
CMSC Board of
Governors...................................................................................50
CMSC Board of Governors - Standing Committee Chairs
..................................51 CMSC Special Projects and
Special Interest Groups
..........................................52 CMSC Continuing
Education
Committee.............................................................53
CMSC Scientic Abstract
Group..........................................................................54
CMSC Administrative Staff
..................................................................................55
Message from the Foundation of the Consortium of MS Centers
......................56 Board of Directors of the Foundation of
the Consortium of MS Centers............57 Future Annual Meetings
......................................................................................65
Table of Contents
5. 72017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana A Message from the
President On behalf of the Board of Governors of the Consortium of
MS Centers (CMSC), I want to welcome you to the 31st Annual Meeting
in historic New Orleans. This meeting is the largest and most
comprehensive multidisciplinary meeting in North America that
focuses on all aspects of MS care and related research. The program
this year is especially exciting and we know it will offer
attendees opportunities for learning, communication, camaraderie
and the kinds of interactions that help inform and build the ideas
that lead to quality MS care practices. The content of the program,
as always, has been designed with input from our membership, needs
assessments from the MS professional community, national events
impacting MS care and ideas from persons with MS. We have designed
the clinical courses, symposia, poster sessions, workshops, dinner
programs and lectures to integrate the science of multiple
sclerosis with the best in clinical practice. The value of the
informal gatherings and casual conversations cannot be
overemphasized. We know that all of you will make the best of
sharing experiences with your old friends, but hopefully will
discover new friends with valuable ideas and opinions on approaches
to move the science and treatment of MS forward. We constantly
strive to improve the program from year to year and rely on your
feedback and critical assessments of the meeting to enhance what we
have done well and try to avoid the weaknesses that are seen not to
meet your needs. The CMSC is and will always be a reflection of the
team approach to MS and this meeting embodies this philosophy. This
is your event, the result of many individuals dedication to
producing a meeting that reflects the broad and diverse membership
of the CMSC. We thank you for coming and for your continued support
of our vibrant and growing organization. Welcome to New Orleans!
Laissez les bon temps rouler! Gary R. Cutter, PhD President,
Consortium of MS Centers Chairman of the Board, Foundation of the
CMSC Gary R. Cutter, PhD
6. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 8 t D^ K On behalf of
the Consortium of Multiple Sclerosis Centers, the International
Organization of Multiple Sclerosis Nurses and the Foundation of the
CMSC, we welcome you to our 31st Annual Meeting in charming New
Orleans, Louisiana. We are very excited to be together again to
celebrate how the world of multiple sclerosis has changed and to
advance our understanding and practice of multiple sclerosis care
and research. We are so glad that you are here to celebrate, learn,
network, and contribute to our legacy of caring and research. The
variable course, symptoms, emotional implications, and therapeutic
requirements of multiple sclerosis necessitate broad-based and
dynamic models of care and research specifically tailored to the
ever-changing nature of the disease. The Annual Meeting curriculum
has been designed to provide clinicians and researchers with the
latest information on the science of MS and the clinical tools and
knowledge to enhance MS care. Our agenda features leading national
and international MS experts who represent the best in clinical
care and research, including a focus on immunology, genetics,
biomarkers, epidemiology and pathophysiology of the disease. On
Wednesday, May 24th the meeting commences with the opening luncheon
and lecture to honor the memory of the late John Kurtzke. Clinical
courses offered each day will meet the needs of our multi-
disciplinary cadre of specialists. Fundamentals in MS Care, Topics
and Trends in MS Rehabilitation, and many more courses for all
specialties and skill levels promise an amazing educational
experience for all. On Wednesday evening, we offer six different
dinner programs. The IOMSN Dinner, celebrating their 20th
Anniversary, will last until the wee hours with music and dancing
beginning at 9:00 p.m. All delegates attending the other dinners,
(Meet the Professor, IOMSRT, the MS Coalition, MS Professionals in
Training, and MS-MHP) are welcome to join the IOMSN fun in the
Great Hall AD in the Convention Center at the conclusion of their
own dinner. Thanks to your input and feedback, this Annual Meeting
is replete with information, opportunities to learn and grow
professionally, and special events full of surprises. We encourage
you to join us in all symposia, clinical courses, dinners,
roundtables, Poster Session, and workshops that reflect your unique
interests. Be sure to attend our independently-supported
educational sessions to enhance your knowledge and skills. Our
expanded Exhibit Hall offers the opportunity to visit our
exhibitors that serve and support MS care and opportunities to
enjoy our meals provided with a touch of New Orleans cuisine.
Friday mornings programming includes a Fun Walk sponsored by the
Foundation, and on Friday evening we will hold an Awards Reception
that will include a celebration of the achievements of our faculty
and our organization. As you can see, the four days are packed with
learning and fun. We are deeply committed to investing in the
recruitment, training and engagement of healthcare professionals in
the field of MS. The Whitaker Research Track, held on Friday,
honors that commitment. The Whitaker track includes presentations
of the results of studies by emerging scholars. We are also excited
to again welcome FCMSC neurology residents and fellows, Morgante
Scholars, and Master MS Learners as delegates to this program and
members of the MS care family. We encourage you to download our
conference App to connect you with attendees and keep you up to
date throughout your time in New Orleans. We are thrilled to
welcome you to NOLA and to the largest gathering of MS Specialists
in North America. While you are with us, we encourage you to
embrace the local customs and unique culture of the Bayou State and
laissez les bons temps rouler! June Halper, MSN, APN-C, MSCN, FAAN
Chief Executive Officer Lisa Taylor Skutnik, PT, MA, MA Chief
Operating Officer
7. 92017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana d d K Basic
Science/Environmental Factors (SC) Review the diagnostic criteria,
phenotypes, and variants of MS to promote accurate diagnosis,
initiation of appropriate therapy and monitoring of outcomes.
Identify the roles and interactions of genetics and epigenetics,
the microbiome, environmental factors, age, comorbidities, and risk
behaviors as factors contributing to pathogenesis and the course of
MS. Psychosocial: Cognition, Depression (CG) Appropriately
integrate tools and strategies into patient assessment that improve
the ability to differentiate between cognitive problems,
depression, and related psychosocial issues. Identify professional
and community resources that support the work of the mental health
team in providing comprehensive care to patients with MS.
Incorporate information obtained through appropriate assessments
into therapeutic plans of care for each identified area of concern.
Comprehensive Care (CC) Examine the various models of care in MS
and the roles and responsibilities of the team members in order to
adapt the most appropriate model for a given practice setting.
Integrate the complex processes that support the provision of
comprehensive care in MS into effective practices and centers
providing evidence-based MS care. Disease Management (DX) Integrate
information about the mechanisms underlying MS relapses,
progression, and gray and white matter pathology as the basis for
monitoring and treating the disease. Summarize methods to monitor
treatment outcomes including patient self-report, automated
self-assessment, new clinician reported outcomes, imaging and
biomarkers to optimize their utilization in clinical practice and
research. Nursing (RN) Analyze and integrate the conceptual
framework under which MS nurses construct individualized
interventions and monitor outcomes in the care of patients with MS.
Evaluate current nursing practice in MS as compared to models of
care utilized in a variety of settings in North America and
internationally. Incorporate specific and evidence-based nursing
skills into the development of plans for individualized care of
patients and families affected by MS. Rehabilitation (RH) Integrate
rehabilitative strategies into the multidisciplinary management of
the sequelae of MS which promote improvements and optimize patients
function and quality of life. Identify MS-specific screening
techniques that facilitate individualized and targeted
rehabilitation services. Symptomatic Management (SX) Analyze common
symptoms of MS and their appropriate pharmacologic and
non-pharmacologic interventions in order to develop strategies
designed to produce disease control and maximize function. Identify
assessment techniques to isolate those factors that affect the
manifestation of the complex symptomatology of MS and differentiate
between acute and chronic MS symptoms. Skills Development (SK)
Critically examine how the expert patient, news media, and social
media affect the relationships between patients with MS, healthcare
professionals, and researchers. Incorporate acquired information
into professional practice skills that enhance comprehensive MS
care and better serve patients, families, and colleagues. Research
(RS) Synthesize emerging data on treatment strategies, such as
early treatment, switching therapies, treating to achieve No
Evidence of Disease Activity (NEDA), personalized treatment, and
post-marketing monitoring of safety and efficacy in order to
promote continuing insights into disease pathology, course, and
management. Review the design and outcomes of clinical trials in
relapsing and progressive MS and disseminate this information to
prepare clinicians to evaluate trial quality and, where
appropriate, integrate findings into clinical practice. TARGET
AUDIENCE The target audience for the annual meeting includes all
healthcare professionals, pharmacists, researchers, and advocates
who are involved in multiple sclerosis care and research.
TRACK/LEARNING OBJECTIVES The CMSC Continuing Education Committee
has identified educational gaps in nine content areas and has
solicited educational sessions in each of these tracks. In addition
to overall objectives, learning objectives specific to each of
those tracks were developed.
8. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 10 PHYSICIANS The
Consortium of Multiple Sclerosis Centers (CMSC) is accredited by
the ACCME to provide continuing medical education for physicians.
The CMSC designates this live activity for a maximum of 21.25 AMA
PRA Category1Credit(s)TM
.Physiciansshouldclaimonlythecreditcommensurate with the extent of
their participation in the activity. PHYSICIAN ASSISTANTS The
American Academy of Physician Assistants (AAPA) accepts
certificates of participation for education activities certified
for AMA PRA Category 1 Credit(s)TM from organizations accredited by
ACCME. NURSES Nurse Practitioner Alternatives (NPA) is accredited
as a provider of continuing nursing education by the American
Nurses Credentialing Centers Commission on Accreditation. This
activity is jointly provided by NPA, CMSC, and The France
Foundation. NPA designates this live activity for a maximum of
21.25 Continuing Nursing Education Credits. Laurie Scudder, DNP,
NP, has served as Nurse Planner for this activity. She has declared
no relevant financial relationships with business and industry.
Code: CMSC052417 PHARMACISTS The France Foundation is accredited by
the Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy education and will award up to 21.25 contact
hours (2.13 CEUs) to pharmacists who (1) complete the activity and
(2) submit a passing posttest ( 70%) and evaluation form via
www.ff-ce.org. There is no fee to participate in this activity.
This is a knowledge-based educational activity. The sessions
offering ACPE credit will be designated in a supplemental
registration handout with a Universal Activity Number (UAN) and
hours of credit. Your CE credits will be submitted electronically
to the CPE Monitor. CE providers must upload participant
information within 60 days from the date the participant completed
the live activity. To ensure your credit fulfillment, you must
submit your posttest, evaluation and credit request via
www.ff-ce.org NO LATER THAN July 10, 2017. Credit requests made
more than 60 days after the activity WILL BE REJECTED BY CPE
Monitor, and are beyond our control. For more information about CPE
Monitor, visit
http://www.nabp.net/programs/cpe-monitor/cpe-monitor- service/.
SOCIAL WORKERS This program is approved by the National Association
of Social Workers (Approval #886535345-9404) for 20.00 Social Work
continuing education contact hours. PSYCHOLOGISTS The Consortium of
Multiple Sclerosis Centers is approved by the American
Psychological Association to sponsor continuing education for
psychologists. The Consortium of Multiple Sclerosis Centers
maintains responsibility for this program and its content. CMSC
offers 45 total contact hours of continuing education in psychology
over the course of this program. Because many accredited sessions
are offered simultaneously, APA affiliated attendees may claim a
maximum of 16.25 CE credits for their participation. OCCUPATIONAL
THERAPISTS The Consortium of Multiple Sclerosis Centers is approved
by the American Occupational Therapy Association, Inc. (AOTA) as a
provider of continuing occupational therapy education. The
Consortium of Multiple Sclerosis Centers maintains responsibility
for this program and its content. CMSC offers more than 63 total
contact hours of continuing education in Occupational Therapy over
the course of this program. Because many accredited sessions are
offered simultaneously, AOTA affiliated attendees may claim a
maximum of 1.8 AOTA CEUs (18 contact hours) for this activity.
CERTIFICATE OF PARTICIPATION A Certificate of Attendance will be
given upon completion of course requirements enabling you to
register your credit with the appropriate licensing boards or
associations. You may apply for other accreditations using the
procedure established by the specific organization. COMMERCIAL
SUPPORT ACKNOWLEDGEMENT This live activity is supported in part by
educational grants received from the following commercial entities:
Americans with Disabilities Act CMSC is committed to making its
programming, including this learning event, accessible to all. If
you have any questions, suggestions or comments regarding the
accessibility of this program, please visit the CMSC Registration
area. ACCREDITATION/CREDIT DESIGNATION STATEMENTS This live
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education through the joint
providership of the Consortium of Multiple Sclerosis Centers
(CMSC), Nurse Practitioner Alternatives (NPA), and The France
Foundation. AbbVie Inc. Biogen Celgene Corporation Mylan Inc. Teva
Pharmaceuticals
9. 112017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana D ^ W BOOTH
PHONE CELL 4M 3M TRUSS6 TRUSS7 TRUSS8
MEETINGROOMMEETINGROOMMEETINGROOM TRUSS9 B2-1 TRUSS10 B2-2 TRUSS11
C-1 TRUSS12 MEETINGROOMMEETINGROOMMEETINGROOM TRUSS13 C-2 TRUSS14
TRUSS15 TRUSS16 D-1D-2 MEETINGROOMMEETINGROOMMEETINGROOM E-1D-3
TRUSS17 TRUSS18 E-2 TRUSS19 TRUSS20 TRUSS21 Box Baler Center
Business OFFICE CENTER BUSINESS II BUSINESS CENTERFirstAid Medical/
MEETINGROOM E-3 TRUSS22 TRUSS23 ATRIUM llawriA Airwall DC BA
10. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 12 D ^ W ABOVE HALLE 254
BALCONY PE17PTPE15 201STR4A 202203204205 211212213 STR4BPT WS WS
219214218217 WS WS 224 STR2A STR2B 225226 PT WS PE2 231232 227
STR1A WS STR1A WS 229228 WS BELOW OPENTO230 WS R R WS STR26
AtriumBridge STR22 236235 PE13 WS STR20 PT STR23 PE14 STR25 WS
241237240 239238242 PT 243 R PT STR28 R WS 245244 STR30STR31 RR WS
WS SERVICECORRIDOR 207 WS WS WS 206 R R WS 208209 BELOW OPENTO
PE4WS TRUSS2 TRUSS4 TRUSS3 STR16 ABOVE HALLC 220 STR3A STR3B 210 R
215 R216 WS 222221223 WSWS TRUSS6 TRUSS5 SO B202B201 SO TRUSS8
TRUSS7 TRUSS9 STR42 TRUSS12 TRUSS11 TRUSS10 PE22 NorthPublicTruss
HALLB1 ABOVE SouthPublicTruss HALLB2 ABOVE SERVICECORRIDOR TRUSS14
TRUSS13 TRUSS16 TRUSS15 TRUSS17 STR27 TRUSS18 STR29 256257255
TRUSS20 TRUSS19 WS SERVICECORRIDOR WS ABOVE HALLD TRUSSPASSAGEWAY
TRUSSPASSAGEWAY R05 RR PT RR R01 WS R03R02 WS R04 WSWS WSWS PE8 PT
PT R07 SO B211 SO B212 SO B213 SO B214 R06 WS SO B21D B216 SO
R09R08 WSWS R R SERVICECORRIDOR STR7 STR19 LaNouvell STR32
BallroomII 253252RR TRUSS22 TRUSS21 WSWS TRUSS23 TRUSSPASSAGEWAY O
ffi ce System Fire Supression 36,448sq.ft. OFFICE GreatHall ABOVE
Below Terrace Below LobbyArea Roof PANTRY20
11. Title 132017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisianaz 'E tE^ z D z
Time Topic/Title Track Chairperson/Speakers Room CMSC COMMITTEE AND
PROJECT MEETINGS 8:30 am 10:00 am Advocacy Marie Namey, RN, MSN,
MSCN David Jones, MD 207 8:30 am 10:00 am Continuing Professional
Education Committee Corey C. Ford, MD, PhD Colleen Harris, MN, NP,
MSCN 210 8:30 am 10:00 am Research Committee Stephen S. Kamin, MD
Peter Riskind, MD, PhD 222 10:00 am 11:30 am Independently
Supported Symposium W D D ^ s d d D ' d h D D ^ s ' E W d W
Faculty: Bruce Cohen, MD Patricia Coyle, MD Great Hall B-C Welcome
and Introduction Diagnosis of MS Treatment of MS Patient Burden;
Quality of Life; Adherence Case Study Conclusions Questions/Answers
11:30 am 1:00 pm K Great Hall A,D 12:15 pm 1:00 pm : D D^ d ^ CC
Aaron Boster, MD Great Hall A,D CLINICAL COURSES 1:15 pm 2:45 pm 1
D: D^ D^ , W ' W CC Allen Bowling, MD, PhD 208-209 Introduction:
History, Botany, Pharmacology Allen Bowling, MD, PhD 1:15 pm 2:45
pm 2 Z W W d D d DX Kathy Tortorice, PharmD, BCPS, Chair Jacquelyn
Bainbridge, PharmD, MSCS Felecia Hart, PharmD, MSCS Ellen Whipple,
PharmD 206 1:15 pm 2:45 pm 3 D Z RH ^ Wd Wd NCS, MSCS 210
12. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana Conference Program 1:15
pm 2:45 pm 4 D D^ CG Amy Sullivan, PsyD, ABPP, Chair 217 1:15 pm
1:45 pm Introduction and Defining the Patient Experience Amy
Sullivan, PsyD, ABPP 1:45 pm 2:15 pm The Role of the Psychiatrist
in an Integrated MS Care Team Morgan Faeder, MD, PhD 2:15 pm 2:45
pm Successful Implementation of Behavioral Medicine into Every Day
Practice; Screening, Assessing and Implementation Claire
Hara-Cleaver, CNP 1:15 pm 2:45 pm 5 d D^ E W W / RN Beverly Layton,
RN, CCRC, MSCN Bonnie Blain, RN, MSCN 207 1:15 pm 2:00 pm Setting
Up Your Practice and Building Care Teams Beverly Layton, RN, CCRC,
MSCN 2:00 pm 2:45 pm Education and How to Structure an Educational
Session Sharon Peters, RN, BN, MSCN 1:15 pm 2:45 pm 6 D^ DZ/ ' h DX
Anthony Traboulsee, MD David K.B. Li, MD 220-221 1:15 pm 1:40 pm
MRI Protocol David K.B. Li, MD 1:40 pm 2:05 pm Gadolinium
Accumulation in the Body Kenneth Maravilla, MD 2:05 pm 2:30 pm
Clinical Guidelines Anthony Traboulsee, MD 2:30 pm 2:45 pm QA Panel
1:15 pm 2:45 pm 7 , W ^^ DX, SK Stephen S. Kamin, MD 222 1:15 pm
2:45 pm 8 / E/ SC ^ E K D^^ Chair 225-227 1:15 pm 1:45 pm How Does
the Immune System Protect Us? Kathleen Costello, MS, ANP-BC, MSCN
1:45 pm 2:15 pm What Causes CNS Inflammation in MS? ^ E K D^^ 2:15
pm 2:35 pm How Do the Current DMTs Affect the Altered Immune
Response in MS? Panel 2:35 pm 2:45 pm QA Panel 2:45 pm 3:00 pm
Break CLINICAL COURSES 3:00 pm 4:30 pm 9 D: D^ D^ , W ' W SC Allen
Bowling, MD, PhD, Chair 208-209 3:00 pm 3:35 pm Addiction,
Psychosis, Efficacy for Psychiatric Conditions Mohini Ranganathan,
MD 3:35 pm 4:10 pm Cognition and Functional Brain Changes in MS
Anthony Feinstein, MD, PhD 4:10 pm 4:30 pm Panel Discussion Panel
3:00 pm 4:30 pm 10 Z W Part 2: Beyond the DMTs SX Kathy Tortorice,
PharmD, BCPS, Chair Jacquelyn Bainbridge, PharmD, MSCS Ellen
Whipple, PharmD 206 3:00 pm 4:30 pm 11 d D W RH Randy Karim PT,
DPT, NCS, CBIS 210 3:00 pm 4:30 pm 12 d d E t D ^ D^ CG Amy
Sullivan, PsyD, ABPP, Chair 217 3:00 pm 3:20 pm Introduction:
Theoretical Basis of Using Mobile Applications to Promote Health
Amy Sullivan, PsyD, ABPP 3:20 pm 3:40 pm Mobile Applications in the
Promotion of Physical Health D W W 3:40 pm 4:00 pm Smartphone
Shrink: Apps to Facilitate Management of Mental Health Symptoms in
MS Patients Michelle Drerup, PsyD 4:00 pm 4:30 pm Ask the Panelists
Panel 3:00 pm 4:30 pm 13 d D^ E W W RN Beverly Layton, RN, CCRC,
MSCN Bonnie Blain, RN, MSCN 207 3:00 pm 3:45 pm Managing Difficult
Conversations in MS Bonnie Blain, RN, MSCN 3:45 pm 4:30 pm
Professional Growth/Sustaining Ourselves Brenda Brelje, RN,
MSCN
13. 152017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana Conference
Program 3:00 pm 4:30 pm 14 D^ DZ/ ' h Z DX Anthony Traboulsee, MD
David K.B. Li, MD 220-221 3:00 pm 3:25 pm MRI Protocol David K.B.
Li, MD 3:25 pm 3:50 pm Gadolinium Accumulation in the Body Kenneth
Maravilla, MD 3:50 pm 4:15 pm Clinical Guidelines Anthony
Traboulsee, MD 4:15 pm 4:30 pm QA Panel 3:00 pm 4:30 pm 15 , W ^^ Z
DX, SK Stephen S. Kamin, MD 222 3:00 pm 4:30 pm 16 / E/ SC ^ E K
D^^ Chair 225-227 3:00 pm -3:40 pm What Environmental Exposures and
Lifestyle Choices Have the Greatest Impact on MS? Kathryn
Fitzgerald, ScD, ScM 3:40 pm 4:20 pm How Does Exercise Influence
the Immune System in MS? Robert Motl, PhD 4:20 pm 4:30 pm QA Panel
4:30 pm 8:00 pm , K Exhibit Hall B1 4:45 pm 6:15 pm Independently
Supported Symposium ' W d Z D d W ^ ^ D d D ^ d DW D / / Ws/ Ws / D
d ^ ' Panel Chair and Presenter: Edward J. Fox, MD, PhD
Co-Presenters: Stephen Krieger, MD, FAAN Lori Mayer, DNP, MSN, RN,
MSCN Great Hall B, C 4:15 pm 4:45 pm Registration and Refreshments
4:45 pm 5:00 pm Welcome, Introduction, and Polling Edward J. Fox,
MD, PhD 5:00 pm 5:20 pm Engaging Patients in Care at Disease Onset:
Shared Decision-Making Science and Stories #1 Science Behind the
Story PeerView Talks: Story Behind the Science Edward J. Fox, MD,
PhD 5:20 pm 5:40 pm Maintaining a Therapeutic Alliance in Highly
Active/Worsening MS: Shared Decision-Making Science and Stories #2
Science Behind the Story PeerView Talks: Story Behind the Science
Stephen Krieger, MD, FAAN 5:40 pm 6:00 pm Managing Expectations and
Allaying Fears About Potential Adverse Effects and Safety
Monitoring: Shared Decision-Making Science and Stories #3 Science
Behind the Story PeerView Talks: Story Behind the Science Lori
Mayer, DNP, MSN, RN, MSCN 6:00 pm 6:15 pm QA and Concluding Remarks
Panel 6:15 pm 8:00 pm K Z , Exhibit Hall B1 6:30 pm 7:30 pm Product
Theater /EZzd D d W t ZD^ d d : D Exhibit Hall B1
14. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 16 Conference Program
INFORMATIONAL AND NETWORKING DINNERS 7:00 pm 11:00 pm International
Organization of MS Nurses (IOMSN) Megan Weigel, DPN, ARNP-C, MSCN,
President June Halper, MSN, APN-C, FAAN, MSCN Great Hall A, D 8:00
pm 9:30 pm Meet the Professor: What is New in MS Treatment The
Benefits in Everyday Clinical Practice DX W ' R02-R04 8:00 pm 9:30
pm International Organization of MS Rehabilitation Therapists
(IOMSRT) Patricia Bobryk, MHS, PT, MSCS, ATP, Co-Chair ^ Wd Wd NCS,
MSCS, Co-Chair Peter Wade, MD, Guest Speaker R05 8:00 pm 9:30 pm MS
Mental Health Professionals (MS/MHP) : t W Frederick W. Foley, PhD,
MSCS, Co-Chair R01 8:00 pm 9:30 pm MS Coalition Lisa Taylor
Skutnik, PT, MA, MA, President R06 8:00 pm 9:30 pm MS Professionals
in Training (MS-PiT) Randall T. Schapiro, MD, FAAN Patricia
Kennedy, RN, CNP, MSCN Brian Hutchinson, PT, MSCS D Hotel - River
Bend Ballroom 9:30 pm - 10:30 pm s D^ t D^K s ^ / ' s ^/' Z
219
15. 172017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisianaz 'E d,hZ^ z D
z Time Topic/Title Track Chairperson/Speakers 7:00 am - 7:45 am E
ZZD^ / D 218 7:00 am 8:00 am / ^ ^ ^ W Z D Z Z D ^ , ' E d D , D ^
Great Hall B, C 6:30 am 7:00 am Registration and Breakfast 7:00 am
7:20 am Relapsing-Remitting MS: Where We Stand Today Stephen
Krieger, MD, FAAN 7:20 am 7:40 am Promiseand Potential
Implicationsof S1P Receptor Modulators Timothy L. Vollmer, MD, FAAN
7:40 am 7:50 am We Are in This Together: Shared Decision-Making in
RRMS Stephen Krieger, MD, FAAN 7:50 am 8:00 am Key Takeaways,
Closing Remarks, Post-test, Audience QA 7:00 am 9:00 am Great Hall
A, D 8:00 am 8:45 am W E D DX : D Great Hall A, D 9:00 am 12:00 pm
D^ W Management 2017 CC, DX Constance B. Easterling, RN, MSN, ARNP,
MSCN, Chair 225-227 9:00 am 9:05 am Welcome and Overview of Program
Constance B. Easterling, RN, MSN, ARNP, MSCN 9:05 am 9:45 am
History of Multiple Sclerosis Thomas J. Murray, MD, ZW D W 9:45 am
10:30 am Nature of MS: Epidemiology, Immunology, Pathophysiology,
Characteristics and Natural History John R. Rinker, II, MD 10:30 am
10:45 am Break 10:45 am 11:25 am Primary Progressive MS: Diagnosis,
Clinical Course, and Long-term Management Patricia K. Coyle, MD
11:25 am 12:05 pm RRMS: Current Treatment Options, Considerations
in Choosing Treatment, Acute Relapse Management Benjamin Thrower,
MD 9:00 am 12:00 pm d d D^ Z W RH Patricia Bobryk, MHS, PT, MSCS,
ATP, Chair 220-221 9:00 am 10:30 am Comprehensive Overview of Rehab
Outcome Measures Part 1 Lacey Bromley, PT, DPT, NCS, MSCS D : Z Kd
D^^ ^W D^^ 10:30 am 10:45 am Break 10:45 am 12:00 pm Comprehensive
Overview of Rehab Outcome Measures Part 2 Lacey Bromley, PT, DPT,
NCS, MSCS D : Z Kd D^^ ^W D^^
16. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 18 Conference Program
9:00 am 12:00 pm D^ E / W RN Colleen Harris, MN, NP, MSCN, Chair
R02-R03 9:00 am 9:05 am Introduction Colleen Harris, MN, NP, MSCN
9:05 am 9:40 am Are Patients Truly Informed about Clinical Trial
Participation? Therese Burke, RN, CNC, MSCN 9:40 am 10:15 am
Treatment Initiation in the Newly Diagnosed Patient Del Thomas, RN,
MSCN Karen Vernon, RN, MSCN 10:15 am 10:45 am Break 10:45 am 11:20
am When Mental Health Issues Interfere with Disease Management
Colleen Harris, MN, NP, MSCN 11:20 am 11:55 am Informing our
Patients About the Risks and Benefits of Therapy Escalation W W ZEW
D^E CNRN, MSCN 11:55 am- 12:00 pm Closing Comments Colleen Harris,
MN, NP, MSCN SYMPOSIA 9:00 am 12:00 pm 1 E^ Z t D / SC Anne H.
Cross, MD, Chair Great Hall A, D9:00 am 9:05 am Introduction Anne
H. Cross, MD 9:05 am 9:40 am Mechanisms of Repair and Delayed
Disability Worsening in MS Provide Different Therapeutic Targets
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath 9:40 am 10:15 am
Do Remyelination Therapies Promote Axonal Survival and Neuronal
Function after Inflammatory Demyelination? Jonah R. Chan, MD, PhD
10:15 am 10:45 am Break 10:45 am 11:20 am From Biotin-responsive
Basal Ganglia Disease to Progressive MS: The Story of a
Serendipitous Discovery Robert Naismith, MD 11:20 am 11:50 am
Imaging Measures of CNS Repair Anne H. Cross, MD 11:50 am 12:00 pm
QA Panel 9:00 am 12:00 pm 2 h t W D^ SC Brian Hutchinson, PT, MSCS,
Chair R05 9:00 am 9:05 am Introduction to Wellness Programs for
People Living with Progressive MS Brian Hutchinson, PT, MSCS 9:05
am 9:40 am Building a Virtual Wellness Model for Progressive MS:
Identifying Resources in Your Community Deborah Miller, PhD, MSAA,
LISW 9:40 am 10:15 am Keeping Progressive MS Patients Engaged in
the Community James Bowen, MD 10:15 am 10:45 am Break 10:45 am
11:20 am Multiple Sclerosis at Home Access (MAHA): Bringing Care
into the Community Kathleen Healey, PhD, APRN 11:20 am 11:55 am A
Community-Based Wellness Model: The MS Achievement Center in
Sacramento Brian Hutchinson, PT, MSCS 11:55 am 12:00 pm Wrap
Up/Conclusions Brian Hutchinson, PT, MSCS 9:00 am 12:00 pm 3 D^ d s
D^ DX D Moderator Panel: K ^ D W Benjamin Segal, MD Mitchell T.
Wallin, MD, MPH R06 9:00 am 9:40 am Progress in Treating
Progressive MS D 9:40 am 10:15 am Rituximab Can be Used to Treat
PPMS instead of Ocrelizumab Panel 10:15 am 10:45 am Break 10:45 am
11:20 am Anti-CD20 Monoclonal Antibody Therapy Should be Used to
Treat SPMS Panel 11:20 am 12:00 pm DMTs Should be Stopped in
Patients with Inactive MS after the Age of 60 Panel
17. 192017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana Conference
Program 9:00 am 12:00 pm 4 D^ h E Z CG John DeLuca, PhD, Chair R07
9:00 am 9:05 am Introduction John DeLuca, PhD 9:05 am 9:20 am
Assessment of Cognitive Impairment in MS Ralph Benedict, PhD,
ABPP-CN, FAPA 9:20 am 10:00 am Structural MRI and Cognition in MS:
Past, Present and Future Ralph Benedict, PhD, ABPP-CN, FAPA 10:00
am 10:40 am Functional MRI and Cognition in MS Helen Genova, PhD
10:40 am 11:10 am Break 11:10 am 11:50 am Cognitive Rehabilitation
in MS John DeLuca, PhD 11:50 am 12:00 pm QA Panel 10:00 am 2:00 pm
, K Exhibit Hall B1 12:00 pm 2:00 pm Luncheon in Exhibit Hall 12:00
pm - 2:00 pm D^ ^ Z Rivergate Room Roundtables 12:30 pm 2:00 pm
Mental Health Roundtable 218 12:30 pm 2:00 pm NARCOMS Roundtable
R01 12:30 pm 2:00 pm NARCRMS Roundtable 222 12:30 pm 2:00 pm Nurse
Roundtable 206 12:30 pm 2:00 pm Pharmacist Roundtable 217 12:30 pm
2:00 pm Physician Roundtable 219 12:30 pm 2:00 pm Rehabilitation
Roundtable 223 12:30 pm 2:00 pm VA Roundtable 207 12:30 pm 2:00 pm
Research Roundtable 208 12:30 pm 2:00 pm Journal Roundtable 210
2:00 pm 4:45 pm D^ W Management 2017 DX, CG, CC Constance B.
Easterling, RN, MSN, ARNP, MSCN, Chair 225-227 2:00 pm 2:45 pm
Current Recommendations and Guidelines in The Use of MRI in MS
Derrick Robertson, MD 2:45 pm 3:25 pm Psychological Impact of MS
Anthony Feinstein, MD, PhD 3:25 pm 3:35 pm Break 3:35 pm 4:10 pm
Neuromyelitis Optica: Diagnosis and Treatment Maureen Mealy, RN,
BSN, MSCN, CNRN 4:10 pm 4:45 pm Womens Issues in MS : ^ ZE D^E
ARNP-C, MSCN 2:00 pm 4:45 pm d d D^ Z W RH Patricia Bobryk, MHS,
PT, MSCS, ATP, Chair 220-221 2:00 pm 3:30 pm The Role of the SLP in
a Comprehensive Care Setting: Much More than Speech D^ ^W MSCS 3:30
pm 3:45 pm Break 3:45 pm 4:45 pm Habitual Retraining ' KdZ SYMPOSIA
2:00 pm 4:45 pm 5 Role of T Cells and B Cells in MS Pathogenesis
Part 1 SC, RS Francisco J. Quintana, PhD, Chair Great Hall A, D
2:00 pm 2:50 pm The Role of Inflammation in the Shaping of Local
Effector and Regulatory T Cell Responses in the CNS Thomas Korn,
MD, PhD 2:50 pm 3:40 pm Neuromyelitis Optica: Pathogenic Insights
on an Autoimmune AQP4 Channelopathy D 3:40 pm 4:00 pm Break 4:00 pm
- 4:45 pm Aquaporin-4-reactive T cells in Pathogenesis of
Neuromyelitis Optica ^ ^ D W
18. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 20 Conference Program
2:00 pm 4:45 pm 6 W D^ DX, SC Brenda Banwell, MD, FAAP, FRCPC,
Chair R05 2:00 pm 2:05 pm Introduction and Welcome Brenda Banwell,
MD, FAAP, FRCPC 2:05 pm 2:45 pm Diagnosis of MS, NMOSD and
MOG-related Demyelination in Pediatric Patients Cheryl Hemingway,
MBChB, PhD 2:45 pm 2:50 pm Questions Panel 2:50 pm 3:30 pm MRI and
Biological Studies in Pediatric MS: Whats New Brenda Banwell, MD,
FAAP, FRCPC 3:30 pm 3:35 pm Questions Panel 3:35 pm 3:45 pm Break
3:45 pm 4:20 pm Clinical Trials and New Therapeutic Agents in
Pediatric MS: Current Challenges and Next Steps Tanuja Chitnis, MD
4:20 pm 4:45 pm Questions Panel 2:00 pm 4:45 pm 7 h D D d D^ W ^ SC
John Nieland, PhD, Chair R02-R03 2:00 pm 2:30 pm Lipid Metabolism a
New Target with High Potential in CNS Diseases John Nieland, PhD
2:30 pm 3:15 pm Fats on Your Brain: The Link Between Lipid
Metabolism and Demyelinating Diseases Angelique Corthals, PhD 3:15
pm 3:30 pm Break 3:30 pm 4:15 pm Looking at Multiple Sclerosis as a
Systemic Disease; Comparing the Effect of the Lipid Metabolism
Blocker, Etomoxir with the Inflammatory Blocker, Interferon-Beta ^
D W 4:15 pm 4:45 pm Modification Like Citrulination and MDA
Adducts, Lipidation and the Immune System; a Mnage a Trois Gone
Wrong in Multiple Sclerosis Kenneth Kastaniegaard, PhD 2:00 pm 4:45
pm 8 h ' / D^ CC, DX Patricia K. Coyle, MD, Chair R06 2:00 pm 2:15
pm Introduction Patricia K. Coyle, MD 2:15 pm 2:30 pm Pediatric MS
Sona Narula, MD 2:30 pm 2:55 pm What Do We Know About Pregnancy?
Patricia K. Coyle, MD 2:55 pm 3:20 pm Perimenopause/Menopause and
MS Dina Jacobs, MD 3:20 pm 3:40 pm Break 3:40 pm 4:05 pm Hormonal
Use in MS Maria Houtchens, MD 4:05 pm 4:25 pm Male Specific Issues
in MS Clyde E. Markowitz, MD 4:25 pm 4:45 pm Panel QA Panel 2:00 pm
4:45 pm 9 / D ^ / W D^ CG Frederick W. Foley, PhD, Co- Chair
Samantha Domingo, PsyD, Co-Chair R07 2:00 pm - 2:45 pm Sexual
Dysfunction in Individuals with MS: Why We Should Focus on
Assessment and Treatment Samantha Domingo, PsyD 2:45 pm 3:30 pm
Assessment of Sexual Dysfunction and Advances in Evidence-Based
Treatments Frederick W. Foley, PhD 3:30 pm 3:45 pm Break 3:45 pm
4:30 pm Bridging the Communication Gap between Patients and
Providers and the Impact of Cycle of Symptoms on Sexual Function
Marie Namey, RN, MS, MSCN 4:30 pm 4:45 pm QA Panel
19. 212017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana Conference
Program 2:00 pm 4:45 pm 10 K t D^ E CC Jacqueline Nicholas, MD,
MPH, Chair 208-209 2:00 pm 2:15 pm Issues Unique to Women
Professionals , K D^ 2:15 pm 2:30 pm Gender Gaps Jacqueline
Nicholas, MD, MPH 2:30 pm 3:15 pm Panel Discussion Panel 3:15 pm
3:30 pm Break 3:30 pm 3:45 pm Mentoring/Networking Mary Alissa
Willis, MD 3:45 pm 4:00 pm Professional Communication Mary Rensel,
MD 4:00 pm 4:45 pm Panel Discussion Panel 4:00 pm 8:30 pm , K
Exhibit Hall B1 5:00 pm - 6:30 pm D^Wd ^/' D 218 5:00 pm 6:30 pm
Independently Supported Symposium W / h DdZ ^ ' Ann D. Bass, MD
Jonathan Calkwood, MD , D Great Hall B, C 5:00 pm 6:30 pm s D^ s
^/' D 219 6:15 pm 8:15 pm Dinner in Exhibit Hall Exhibit Hall B1
6:15 pm 8:15 pm WK^dZ ^^^/KE Exhibit Hall B2 6:45 pm 7:45 pm
Product Theater / 'D^ d ' d Wendy Booker D^ W W Advocate Exhibit
Hall B1 8:30 pm 9:30 pm Independently Supported Symposium d d E ^ ,
W D^ W h E D^ D^ D ' Panel: W ^ ^ D Dr Sarah Morrow, MD, FRCPC, MS
K' D Amy Perrin Ross, MS specialist nurse : ^ advocate W ' advocate
R02-R03
20. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 22z 'E Z/ z D z Time
Topic/Title Track Chairperson/Speakers 7:00 am 9:00 am Great Hall
A, D 7:45 am 8:45 am John Whitaker Memorial Lecture , Z W D^ / d D^
W SC Jerry S. Wolinsky, MD, Moderator Emmanuelle Waubant, MD, PhD
Great Hall A, D 9:00 am 12:00 pm t d SC Michael K. Racke, MD, Chair
Great Hall A, D9:00 am 9:15 am Introduction Michael K. Racke, MD
9:15 am 9:45 am MiRNAs as Potential Risk Factors for Multiple
Sclerosis Z W 9:45 am 10:15 am MiR-223 Modulates Myeloid-derived
Suppressor Cells in Multiple Sclerosis and its Animal Model Laura
Piccio, MD, PhD 10:15 am 10:45 am MicroRNA Regulation of Astrocyte
Reactivity Jack Antel, MD 10:45 am 11:00 am Break 11:00 am 11:15 am
Establishing the Relationship of Quantitative Vibratory Sensation
and Sensory Cortical Areas in Multiple Sclerosis Nora Fritz, PhD,
PT, DPT, NCS 11:15 am 11:30 am A Single-Session Training of Ball
Throwing Exercise Improves Balance Control in Individuals with
Multiple Sclerosis Yunju Lee, PhD 11:30 am 11:45 am The Feasibility
of a Patient Informed, Racially Targeted, Home-Based Exercise
Program for Black Persons with Multiple Sclerosis , ^ 11:45 am
12:00 pm Capitalising on the Opinions of Persons with MS to Inform
the Main Trial: Participant Opinions from Participation in a
Feasibility Study Yvonne Learmonth, PhD 9:00 am 12:00 pm D^ W ^
Management 2017 SK, RH, SX Constance B. Easterling, RN, MSN, ARNP,
MSCN, Chair 225-227 9:00 am 9:05 am Welcome and Overview of Program
Constance B. Easterling, RN, MSN, ARNP, MSCN 9:05 am 9:50 am
Integrative Medicine in MS Megan Weigel, DPN, ARNP-C, MSCN 9:50 am
10:30 am Movement and Gait Disorders Lacey Bromley, PT, DPT, MSCS
10:30 am 10:40 am Break 10:40 am 11:20 pm Managing Pain and Sensory
Symptoms Marie Moore, MSN, ARNP, MSCN 11:20 am - 12:00 pm Managing
Symptoms Affecting Activities of Daily Living d Kd D^^ 9:00 am
12:00 pm d d D^ Z W RH Patricia Bobryk, MHS, PT, MSCS, ATP, Chair
220-221 9:00 am 10:30 am Highlights from the 6th International
Symposium on Gait and Balance in MS: Sensory Contributions Michelle
Cameron, MD, PT, MCR Gail Widener, PT, PhD W KdZ MSCS 10:30 am
10:45 am Break 10:45 am 12:00 pm Getting Started in Clinical
Research ' Z W
21. 232017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana Conference
Program SYMPOSIA 9:00 am 12:00 pm 11 D E^ / D E^ D D^ SC Ari
Waisman, PhD, Chair R06 9:00 am 9:10 am Introduction Ari Waisman,
PhD 9:10 am 9:45 am Microglia Responses during CNS Inflammation Ari
Waisman, PhD 9:45 am 10:20 am Distinct Roles for
MicrogliaMacrophages during CNS Inflammation Dorian McGavern, PhD
10:20 am 10:50 am Break 10:50 am 11:25 am Innate Immunity and
Dementia Marco Colonna, MD 11:25 am 12:00 pm Brain Invading
Phagocytes: The True Executers of CNS Tissue Damage Burkhard
Becher, PhD 9:00 am 12:00 pm 12 E W D^ K , / D CC Allen Bowling,
MD, PhD, Chair R02-R03 9:00 am 9:35 am Integrative Medicine,
Non-Pharmacologic Symptomatic Therapy, Overview of Nutrition and MS
Allen Bowling, MD, PhD 9:35 am 10:15 am Focus on Nutrition: Obesity
and MS Tanuja Chitnis, MD 10:15 am 10:45 am Break 10:45 am 11:20 am
Focus on Nutrition: Biotin and MS Ayman Tourbah, MD, PhD 11:20 am
12:00 pm Culinary Medicine in Clinical Delivery Timothy S. Harlan,
MD, FACP 9:00 am 12:00 pm 13 ^ D^ t t t t About It CG Rosalind
Kalb, PhD, Chair R01 9:00 am 9:30 am A Familys Loss Fuels Research
to Understand Suicide Risk in MS Rosalind Kalb, PhD Devin Tomiak
9:30 am 10:15 am Depression in MS: Etiology, Epidemiology and the
Risk of Suicide Anthony Feinstein, MD, PhD 10:15 am 10:45 am Break
10:45 am 11:45 am Suicide: Strategies for Prevention and Coping
with its Aftermath Doreen Marshall, PhD 11:45 am 12:00 pm Panel
Discussion Panel 9:00 am 12:00 pm 14 D ^ ^ D^ CC, SX, DX Kathleen
Costello, MS, ANP-BC, MSCN, Chair R05 9:00 am 9:15 am Welcome and
Introductions Kathleen Costello, MS, ANP-BC, MSCN 9:15 am 10:15 am
Complex Disorders of Mood Associated with MS: Assessment and
Management Adam Kaplin, MD, PhD 10:15 am 10:45 am Break 10:45 am
11:20 am Complex Mobility Issues in MS: Assessment and Management ^
E K D^^ 11:20 am 11:55 am Complex Visual Symptoms Associated with
MS: Assessment and Management Robert Shin, MD 11:55 am 12:00 pm
Conclusion Kathleen Costello, MS, ANP-BC, MSCN 10:00 am 2:00 pm , K
Exhibit Hall B1 12:00 pm 2:00 pm Luncheon in Exhibit Hall Exhibit
Hall B1 12:15 pm 1:15 pm Product Theater KZsh^ / / h W ^ ' / d
Meghan Kinnetz, MSN, ARNP, FNP-BC, MSCN Exhibit Hall B1 2:00 pm
5:00 pm D^ W ^ Management 2017 SX, CC, CG Constance B. Easterling,
RN, MSN, ARNP, MSCN, Chair 225-227 2:00 pm 2:40 pm Managing Sleep
Disorders David Brandes, MS, MD, FAAN, MSCS 2:40 pm 3:20 pm
Managing Symptoms of Elimination Dysfunction Marie Namey, RN, MS,
MSCN 3:20 pm 3:30 pm Break 3:30 pm 4:15 pm Invisible Symptoms:
Depression, Cognitive Dysfunction W W D^E ZEW MSCN 4:15 pm 5:00 pm
Effect of MS on Sexual Function, Pregnancy and Menopause Mary Kay
Fink, MSN, ARNP, MSCN
22. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana Conference Program 2:00
pm 5:00 pm 15 Role of T Cells and B Cells in MS Pathogenesis Part 2
SC Francisco J. Quintana, PhD, Chair Great Hall A, D 2:00 pm 2:40
pm Role of GM-CSF in the Pathogenic Function of Th-17 cells in
Autoimmune CNS Demyelination Abdolmohamad Rostami, MD, PhD 2:40 pm
3:20 pm The Relative Importance of Th1 versus Th17 Cells in MS
Benjamin M. Segal, MD 3:20 pm 3:35 pm Break 3:35 pm 4:15 pm
Environmental Regulation of the T Cell Response Francisco J.
Quintana, PhD 4:15 pm 5:00 pm Novel Cytokine Pathways in MS
Alexandre Prat, MD, PhD, FRCPc PLATFORM PRESENTATIONS 2:00 pm 4:00
pm W CG : t W D R07 2:00 pm - 2:17 pm CG01 Goal Attainment in a MS
Cognitive Intervention Study Ana Todd, PhD, RN 2:17 pm - 2:34 pm
CG02 The Mediating Role of Cognitive Fatigue on the Relationship
Between Anxiety and Illness Intrusiveness in Multiple Sclerosis
Patients Caroline Altaras, BS 2:34 pm - 2:51 pm CG03 The
Relationship Between Social Cognition Impairments and Fatigue,
Depression and Anxiety in Individuals with Multiple Sclerosis Helen
Genova, PhD 2:51 pm - 3:06 pm CG04 Shifting to the Positive:
Findings from the Resilience Questionnaire in MS d W D^ BScN 3:06
pm - 3:23 pm CG05 The Contribution of Stigma on Depression Symptoms
and Depression Status Among Individuals Living with Multiple
Sclerosis Margaret H. Cadden, MS 3:23 pm - 3:40 pm CG06 The Impact
of Natalizumab on Health-Related Quality of Life in Patients with
Secondary-Progressive Multiple Sclerosis Nolan Campbell, PhD 3:40
pm - 3:57 pm CG07 Mindfulness Training Vs. Adaptive Cognitive
Training: Impact on Emotion Dysregulation and Cognitive Functioning
Ruchika S. Prakash, PhD 2:00 pm 4:00 pm D / d DX R06 2:00 pm - 2:17
pm DX01 Rapid and Robust B Cell Depletion in Preliminary Results of
a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20
Mab, in RMS Patients Z W 2:17 pm - 2:34 pm DX02 Durable Efficacy of
Alemtuzumab on Clinical and MRI Outcomes over 6 Years in Care-MS II
Patients with Active RRMS with Relapse Between Courses 1 and 2
Barry A. Singer, MD 2:34 pm - 2:51 pm DX03 When Should
Disease-Modifying Treatments be Discontinued in Patients with
Multiple Sclerosis: An Evidence-Based Review with Expert
Recommendations Devyn Parsons, BSc 2:51 pm - 3:06 pm DX04 Benefits
of Cladribine Tablets in Patients with Multiple Sclerosis Free from
Clinical and Radiological Indicators of Disease Activity in the
CLARITY EXTENSION Study Z D 3:06 pm - 3:23 pm DX05 Efficacy and
Safety of Ozanimod in the Blinded Extension (120 weeks) of
RADIANCE, a Phase 2 Trial in Relapsing Multiple Sclerosis ^ W 3:23
pm - 3:40 pm DX06 Use of Rituximab Therapy in Improving Radiologic
Evidence of Disease in Patients with Multiple Sclerosis Mary Ann
Picone, MD 3:40 pm - 3:57 pm DX07 Preliminary Results of the OPERA
I and OPERA II Open-Label Extension Study Robert T. Naismith, MD
2:00 pm 4:00 pm Z / RH R01 2:00 pm - 2:20 pm RH01 Dynamic Stability
During Gait Is Altered in Persons with Multiple Sclerosis Who Have
a Falls History Compared to Non-Fallers and Healthy Controls Jessie
Huisinga, PhD 2:20 pm - 2:40 pm RH02 The Relationship Between
Variability of the Center of Mass and Base of Support Is Altered
During Gait in Persons with Multiple Sclerosis Jessie Huisinga, PhD
2:40 pm - 3:00 pm RH03 Persons with Multiple Sclerosis Increase
Their Dynamic Margin of Stability during Gait Jessie Huisinga, PhD
3:00 pm - 3:20 pm RH04 Physical Activity and Physical Function in
Older Adults with Multiple Sclerosis D^ Wd 3:20 pm - 3:40 pm RH05
Longitudinal Relationships Between Moderate and Vigorous Physical
Activity, Fatigue and Depression in Pediatric MS Samantha Stephens,
PhD 3:40 pm - 4:00 pm RH06 The Efficacy of Functional Electrical
Stimulation (FES) Cycling for Improving Physiological Function in
People with MS with Severe Mobility Impairment Thomas A Edwards,
BKin
23. 252017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana Conference
Program 2:00 pm 4:00 pm D^ ^ D CC, SX R02-R03 2:00 pm - 2:20 pm
CC01 What Patients Expect from Their MS Nurse: Canadian Survey
Results Colleen Harris, MN, NP, MSCN, MSCS 2:20 pm - 2:40 pm CC02
Self-Reported Personal Impact of MS Wellness Programs D^ KdZ 2:40
pm - 3:00 pm CC03 Shared Decision Making: Connecting Clinicians and
Patients to Improve Patient Outcomes James D. Bowen, MD 3:00 pm -
3:20 pm CC04 Patient Input into Multiple Sclerosis Quality and
Outcome Measures : D 3:20 pm - 3:40 pm CC05 Factors Associated with
Pediatric Onset Multiple Sclerosis Slowed Gait: Does Mood Matter?
Mary R. Rensel, MD 3:40 pm - 4:00 pm CC06 Goals of Care in People
Living with Advanced Multiple Sclerosis Rachael Stacom, ANP, MSCN
4:00 pm 4:15 pm Break WORKSHOPS 4:15 pm 5:45 pm 1 h d D^ CC Riley
Bove, MD, Chair R05 4:15 pm 4:30 pm Introduction and Overview:
Patient Disease Management Tools in MS Riley Bove, MD 4:30 pm 5:05
pm Digital Tools to Increase Physical Activity Valerie Block, PT,
DPTSc 5:05 pm 5:40 pm Digital Tools to Increase Overall Well-being,
Including Emotion and Cognition Adam Kaplin, MD, PhD 5:40 pm 5:45
pm Summary: An Expanding Digital Toolkit to Enhance MS Care Riley
Bove, MD 4:15 pm 5:45 pm 2 W D d W d CC Christopher C. Luzzio, MD,
Chair R01 4:15 pm -4:45 pm Engineering Projects for Rehabilitation,
Community Service, and Empowering our Patients Christopher C.
Luzzio, MD 4:45 pm 5:15 pm Tools and Methods for Design and
Fabrication Christopher Westphal, PhD 5:15 pm 5:45 pm Human Factors
Amrish Chourasia, PhD 4:15 pm 5:45 pm 3 d / W W h Data d s D^ CC
Jodie K. Haselkorn, MD, MPH, Co-Chair Mitchell T. Wallin, MD, MPH,
Co-Chair 222 4:15 pm 4:25 pm Introduction Jodie K. Haselkorn, MD,
MPH 4:25 pm 4:50 pm Using MS RegistriesDatasets to Optimize Patient
Outcomes Mitchell T. Wallin, MD, MPH 4:50 pm 5:15 pm Rigorous
Ascertainment of Disease and Outcomes is Key for Population- Based
Care Using Large Data W. Joel Culpepper, PhD, MA 5:15 pm 5:35 pm
Clinical Case: Improving Patient-Centered Care with Large Data
Heidi W. Maloni, PhD, ANP-BC, CCRN, MSCN 5:35 pm 5:45 pm Discussion
and Questions Panel 4:15 pm 5:45 pm 4 W d t RS Andrew D. Goodman,
MD Eileen Scheid, RN, MSN, MSCN R06 4:15 pm 4:35 pm PI
Responsibilities Andrew D. Goodman, MD 4:35 pm 4:55 pm Time is
Money Eileen Scheid, RN, MSN, MSCN 4:55 pm 5:15 pm Who, When and
Where Jessica Robb, MD 5:15 pm 5:30 pm Case Study: Putting the
Pieces Together Panel 5:30 pm 5:45 pm QA Panel 4:15 pm 5:45 pm 5 d
D^ CC Bryan Walker, MHS, PA-C, Chair Edward J. Fox, MD, PhD, FAAN
Stephanie Agrella, RN, MSN, APRN, ANP-BC, MSCN Mark Skeen, MD
R02-R03 4:15 pm 5:45 pm 6 ^ D D^ RS Robert Herndon, MD, Chair
208-209 4:15 pm 5:00 pm Scales for Clinical Use in MS Robert
Herndon, MD 5:00 pm 5:45 pm Quality of Life Scales and Sexuality
Scales Frederick W. Foley, PhD, MSCS
24. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 26 Conference Program
4:15 pm 5:45 pm 7 E K ^ SC Dean Wingerchuk, MD, MSc, FRCPC, Chair
220-221 4:15 pm 4:40 pm Neuromyelitis Optica Spectrum
Disorders-Basic Science Update May Han, MD 4:40 pm 5:05 pm
Diagnosis of Neuromyelitis Optica Spectrum Disorders Dean
Wingerchuk, MD, MSc, FRCPC 5:05 pm 5:30 pm Treatment of
Neuromyelitis Optica Spectrum Disorders Ilana Katz Sand, MD 5:30 pm
5:45 pm QA Panel 4:15 pm 5:45 pm 8 t , t Z RS ' Z W Z D 223 4:15 pm
4:30 pm Introduction of NARCOMS and NARCRMS-Why are they Different?
What is the History? ' Z W Z D 4:30 pm 4:45 pm A Clinical Registry
Experience Tanuja Chitnis, MD 4:45 pm 5:00 pm What We Have Learned
from NARCOMS Amber Salter, PhD ' W 5:00 pm 5:15 pm What We May
Learn from NARCRMS Z D 5:15 pm 5:30 pm Estimating the Prevalence of
MS from Registries Mitchell T. Wallin, MD, MPH Ruth Ann Marrie, MD,
PhD, FRCPC 5:30 pm 5:45 pm Panel Discussion and QA Panel 4:15 pm
5:45 pm 9 t D^ D ^ RS Lynne Shinto, ND, MPH, Chair Nicholas G.
LaRocca, PhD 206-207 4:15 pm 4:30 pm Considerations in Conducting
Dietary Intervention Trials in People with Multiple Sclerosis Ellen
Mowry, MD 4:30 pm 4:45 pm Exercise and Multiple Sclerosis:
Overview, Gaps, and Next Steps Robert Motl, PhD 4:45 pm 5:00 pm
Emotional Wellness: Gaps and Opportunities in Mind-Body Research
Lynne Shinto, ND, MPH W Ehde, PhD 5:00 pm 5:15 pm What NOT To Do If
You Want Your Grant Application Funded Nicholas G. LaRocca, PhD
5:15 pm 5:45 pm QA Panel 6:00 pm 7:30 pm Independently Supported
Symposium MS S S S S D d D W / D D d ^ ' ^ E K D^^ Chair Stephanie
Agrella, MSN, RN, APRN, ANP-BC, MSCN Great Hall B, C 6:00 pm 6:05
pm Welcome, Pre-Test, and Overview of Symposium Format ^ E K D^^
6:05 pm 6:20 pm Sequencing ^ E K D^^ 6:20 pm 6:35 pm Switching
Stephanie Agrella, MSN, RN, APRN, ANP-BC, MSCN 6:35 pm 6:50 pm
Escalation ^ E K D^^ 6:50 pm 7:05 pm Symptom Management Stephanie
Agrella, MSN, RN, APRN, ANP-BC, MSCN 7:05 pm 7:20 pm Questions and
Answers ^ E K D^^ Stephanie Agrella, MSN, RN, APRN, ANP-BC, MSCN
7:20 pm 7:25 pm Concluding Remarks ^ E K D^^ Stephanie Agrella,
MSN, RN, APRN, ANP-BC, MSCN 7:25 pm 7:30 pm Post-Test and Adjourn
7:30 pm 8:15 pm D^ Z Rivergate Room
25. 272017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisianaz 'E ^ dhZ z D
z Time Topic/Title Track Chairperson/Speakers 7:00 am 9:00 am 8:00
am 8:45 am W D / d D ^ / Z D ^ E W SC Brian G. Weinshenker, MD
Great Hall A, D 9:00 am 12:00 pm d d D^ Z W RH Patricia Bobryk,
MHS, PT, MSCS, ATP, Chair 220-221 9:00 am 10:30 am Bowel and
Bladder Dysfunction: What Role Does Rehab Play? Marlene
Murphy-Setzko, MD 10:30 am 10:45 am Break 10:45 am 12:00 pm
Adaptive Sports ' D dZ^ SYMPOSIA 9:00 am 12:00 pm 16 D SC Tanuja
Chitnis, MD, Chair Great Hall A, D9:00 am 9:15 am Introduction and
Overview Tanuja Chitnis, MD 9:15 am 9:45 am Immune Modulation by
the Gut Microbiome in MS Sergio Baranzini, PhD 9:45 am 10:15 am
Gender-Specific Influence of the Early-life Microbiota in
Experimental Autoimmune Encephalomyelitis Laura Cox, PhD 10:15 am
10:30 am Break 10:30 am 11:00 am The Gut Microbiome in Pediatric MS
Emmanuelle Waubant, MD, PhD 11:00 am 11:30 am Microbiome-Directed
Therapeutics for MS Tanuja Chitnis, MD 11:30 am 12:00 pm QA Panel
9:00 am 12:00 pm 17 D ^ DX, CC Ruth Ann Marrie, MD, PhD, FRCPC,
Chair 225-227 9:00 am 9:20 am Introduction Terminology, What is
Comorbidity, and Prevalence of Medical Comorbidity Ruth Ann Marrie,
MD, PhD, FRCPC 9:20 am 10:15 am Psychiatric Comorbidity in MS
Anthony Feinstein, MD, PhD 10:15 am 10:30 am Break 10:30 am 11:05
am Effects of Comorbidity on Outcomes in MS Ruth Ann Marrie, MD,
PhD, FRCPC 11:05 am 12:00 pm Influence of Comorbidity on
Rehabilitation D W KdZ
26. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 28 Conference Program
9:00 am 12:00 pm 18dD^ t t t t t SC Michael K. Racke, MD, Chair
217-219 9:00 am 9:45 am Rationale for Stem Cell Transplant in
Multiple Sclerosis Michael K. Racke, MD 9:45 am 10:30 am
Mechanistic Rationale and Insights from Monoclonal Antibody Therapy
vs. Autologous Hematopoietic Stem Cell Transplantation for
Treatment of Multiple Sclerosis Paolo Muraro, MD, PhD 10:30 am
10:45 am Break 10:45 am 11:30 am Rationale for Selecting the
Transplant Conditioning Regimen for the BEAT- MS Trial George
Georges, MD 11:30 am 12:00 pm Panel Discussion Michael K. Racke, MD
Paolo Muraro, MD, PhD George Georges, MD Dawn Smilek, MD, PhD 9:00
am 12:00 pm 19 / d W CG Deborah Miller, PhD, LISW, MSAA, Chair 223
9:00 am 9:05 am Introducton Deborah Miller, PhD, LISW, MSAA 9:05 am
9:40 am The Family Caregiving Experience Deborah Miller, PhD, LISW,
MSAA 9:40 am 10:15 am The Stress and Burnout that Results from
Family Caregiving D ^ W 10:15 am 10:45 am Break 10:45 am 11:20 am
Interventions to Support Family Members as Caregivers who
Experience Stress and Burnout Lucille Carriere, PhD 11:20 am 11:55
am Case Discussion Panel 11:55 am 12:00 pm Wrap Up/Conclusions
Deborah Miller, PhD, LISW, MSAA 9:00 am 12:00 pm 20 Dd d D^ ^ CC
Edward J. Fox, MD, PhD, FAAN, Chair 208-209 9:00 am 9:15 am
Introduction Edward J. Fox, MD, PhD, FAAN 9:15 am 9:55 am Early
Treatment of MS - Decision Process Sibyl Wray, MD 9:55 am 10:35 am
NEDA - Realistic Goal? Corey Ford, MD, PhD 10:35 am 10:50 am Break
10:50 am 11:30 am Methods to Develop Algorithms for DMT Use Edward
J. Fox, MD, PhD, FAAN 11:30 am 12:00 pm Open Discussion Faculty
12:00 pm Adjourn
28. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana
7:00-8:00amIndependentlySupportedSymposium
EvaluatingSphingosine1-PhoshateReceptorModulatorsforRelapsing-RemittingMultipleSclerosis:
HigherGoals,NovelDrugsBreakfast
8:00-8:45amPresidentialLecture:NewMcDonaldCriteria 8:45-9:00am
9:00-10:00amCoreConcepts forthe MSNurse: International CaseBased
Perspectives FundamentalsofMSCare:PartI
ACase-basedApproachtoDisease Management2017 Current Topicsand
TrendsinMS Rehabilitation: Part1 Symposia1 CNSRepairand
WaystoMeasure It Symposia2 UniqueWellness Approachesto
ProgressiveMS Symposia3 Debatesover Controversies inMS Symposia4
Cognitionin MS:Updateon Assessment, Neuropathology and
Rehabilitation 10:00-12:00pm ExhibitHall Open 12:00-12:30pm
LuncheoninExhibitHall12:30-2:00pmMentalHealthRoundtable
NARCOMSRoundtable NARCRMSRoundtable NurseRoundtable
PharmacistRoundtable PhysicianRoundtable RehabilitationRoundtable
VARoundtable ResearchRoundtable JournalRoundtable
2:00-4:00pmCurrent Topicsand TrendsinMS Rehabilitation: Part2
Fundamentalsof MSCare:Part2 ACase-based Approach toDisease
Management 2017 Symposia5 RoleofTCells andBCellsin MSPathogenesis
Part1 Symposia6 PediatricMS Symposia7 UseofLipid Metabolism
Blockersand Modifiersfor theTreatmentof MS:AParadigm Shift
Symposia8 Updateon GenderIssues inMS Symposia9 Interdisciplinary
Approachto Managing SexualityIssues inPatientswith MS Symposia10
Building Opportunities andConnecting WomenMS Neurologists
4:00-4:45pm ExhibitHall Open 4:45-5:00pmBreak
5:00-6:00pmIndependentlySupported Symposium
PracticalInsights:Understanding AutoimmuneEventsAssociated
withLEMTRADA(alemtuzumab) VAMSCoEand VASIGBusiness Meeting
MS-PiTSIG Meeting 6:00-6:15pm 6:15-6:30pm POSTERSESSIONDinnerin
ExhibitHall6:30-6:45pm
6:45-7:45pmProductTheater-IntroducingGatherMS 7:45-8:15pm
8:15-8:30pmBreak 8:30-9:30pmIndependentlySupportedSymposium
TheThursdayNightLateShowHealthcareProfessionalsandMSPatientsDiscussUnmetNeedsinMSCareandtheCommunicationDivide
30 W ' Thursday,May25
29. 312017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana W '
Friday,May26 7:00-7:45amBreakfast
7:45-8:00amJohnWhitakerMemorialLecture:HowResearchonPediatricMSCanInformThoughtsonMSPathogenesis
8:00-8:45am 8:45-9:00amBreak 9:00-10:00amFundamentals ofMSCare:
Part3 ACase-based Approach toSymptom Management 2017 Whitaker Track
Current Topicsand Trendsin MSRehabili- tation:Part3 Symposia11
FunctionofMyeloidCells inCNSInflammation withaFocusonMicroglia
CellsandCNS-invading MacrophagesDuringMS Symposia12
ANewParadigmofMS Care:OptimizingHealth throughtheIntegrationof
Lifestyle,Alternative,and ConventionalMedicine Symposia13
Depression Suicidein MS:What WeKnow andWhat WeCanDo AboutIt
Symposia14 Effective Management Strategies forComplex Symptoms ofMS
10:00-11:30amExhibitHall Open11:30-12:00pm 12:00-12:15pm Luncheonin
ExhibitHall
12:15-1:15pmProductTheater-OCREVUS(ocrelizumab)InjectionforIntravenousUse
1:15-2:00pm 2:00-3:00pmFundamentals ofMSCare: Part4 ACase-based
Approach toSymptom Management 2017 PlatformPresentations
Psychosocial:Cognition, Depression PlatformPresentations
DiseaseManagement, ImagingandTherapeutics PlatformPresentations
Rehabilitation Interventions PlatformPresentations
ComprehensiveCareinMSandSymptom Management Symposia15 RoleofT
CellsandB CellsinMS Pathogenesis Part2 3:00-4:00pm 4:00-4:15pmBreak
4:15-5:00pmWS1 Using DigitalTools toEnhance MSCare WS2 Empowering
Patients byMaking Them Partofthe Engineering Team WS3 Treating
Individuals and Providing Population BasedCare UsingLarge Data WS4
Evaluating Potential Clinical Trials:What toKnow WS5 TheCol-
laborative Approachto MSCare WS6 Scalesand Measuresin MS WS7
Neuromy- elitisOptica Spectrum Disorders WS8 WhatHave WeLearned
from Registries? WS9 Wellnessin MS: Methodol- ogyfor Clinical
Studies 5:00-5:45pm 5:45-6:00pmBreak
6:00-7:30pmIndependentlySupportedSymposium
MS4:Sequencing,Switching,EScalation,andSymptomManagement
7:30-8:15pmCMSCAwardsReception
30. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 32 W ' Saturday,May27
7:00-8:00amBreakfast 8:00-8:45amDonaldPatyMemorialLecture
InductionorAggressiveTreatmentforMultipleSclerosis:IsitRightforMost,SomeorNoPatients?
8:45-9:00amBreak 9:00-12:00pmCurrentTopics andTrendsinMS
Rehabilitation:Part4 Symposia16 Microbiome Symposia17
Comorbiditiesin MultipleSclerosis Symposia18 BEAT-MS:Who,What,
Why,WhenandWhere? Symposia19 InformalCaregiving:
FromTheorytoPractice Symposia20 DMTTreatment DecisionsinMS:
SortingouttheData 12:00Adjourn
31. 332017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana ^ Lectures,
Dinners, Fundamentals of MS Care, Current Topics and Trends in MS
Rehabiliation, Core Concepts for the MS Nurse, Whitaker Track JOHN
F. KURTZKE MEMORIAL LECTURE: MS COMPREHENSIVE CARE-A TEAM SPORT The
opening lecture of the 31st CMSC Annual Meeting is presented in
memory of the late John F. Kurtzke, MD who was a strong proponent
of the team approach in MS care. Dr. Boster will share how his team
works collaboratively with the patient and family to effectively
deal with the complexities of the disease. This lecture will set
the stage for four days filled with information, teamwork, and
networking. Level of Information: Basic PRESIDENTIAL LECTURE: NEW
MCDONALD CRITERIA Diagnostic criteria for multiple sclerosis have
undergone successive revision and refinement. All of the versions
of diagnostic criteria represent a compromise between sensitivity,
to facilitate making the diagnosis efficiently and now that
treatment options exist to allow appropriate early institution of
disease therapy, and specificity, to lessen the risk of
misdiagnosis. An international consensus workshop recently was
convened to assess the performance of the current 2010 McDonald
Criteria to address these competing goals and review new data that
have accumulated since the last panel meeting that led to the 2010
Criteria. This presentation will summarize those discussions and
the resultant proposed revisions to the McDonald Criteria. Level of
Information: Basic, Intermediate, Advanced JOHN WHITAKER MEMORIAL
LECTURE: HOW RESEARCH ON PEDIATRIC MS CAN INFORM THOUGHTS ON MS
PATHOGENESIS MS susceptibility and its evolution are under the
influence of complex genetic and environmental risk factors.
Studying patients with disease onset 20-30 years earlier than
average age of MS onset allows focus on exposures that are likely
more relevant to MS onset than similar studies in adults with the
disease who had a life time of exposures. In addition, patients
with MS onset at a very young age may have a larger burden of
genetic and environmental factors, possibly making these easier to
identify. Studying the complex interplay between genetic and
environmental risk factors in the same young patients is likely
going to help understand biological processes ultimately resulting
in MS onset and its progression and might lead to a new
understanding of MS in general. Although pediatric MS represents
about 5% of all MS cases, it can be leveraged to advance MS
research in general. Furthermore, treating children with MS is
challenging as all the medications approved for MS have been tested
only in subjects 18 years and above. Confirming similarities and
differences in MS pathophysiology in children vs. adults will help
confirm if drugs for adult MS are also expected to work in children
with the disease. Level of Information: Intermediate, Advanced
DONALD PATY MEMORIAL LECTURE: INDUCTION OR AGGRESSIVE TREATMENT FOR
MULTIPLE SCLEROSIS-IS IT RIGHT FOR MOST, SOME OR NO PATIENTS?
Aggressive treatments are generally administered as induction
agentsstrong immunointerventions that provide rapid suppression of
the immune- mediated inflammatory disease (Martinelli, Comi 2005).
Mitoxantrone, alemtuzumab and myeloablation with autologous stem
cell transplantation are examples. Natalizumab, a potent
maintenance treatment with attendant serious adverse effects, may
also be considered aggressive. The benefits of aggressive induction
were demonstrated in a randomized clinical trial of mitoxantrone
versus interferon beta-1b for 6 months; over 3 years, the
differences in outcome were robust and would be perceived by
patients and their clinicians. However, direct evidence for
benefits of aggressive treatments in all patients with MS is
lacking and the arguments in support are inferential. The arguments
in favor of routine use of aggressive treatments are: 1. MS is a
uniformly severe disease accompanied by accelerated brain atrophy
that will ultimately lead to progressive MS. 2. It is not possible
to predict which patients will or will not do poorly. 3. There is a
narrow window for effective intervention. 4. Aggressive/induction
treatments are more efficacious than conventional treatments. 5.
Treatments are adequately safe. 6. Aggressive suppression of
disease (no evidence of disease activity, NEDA) is attainable and
leads to better short and long term outcomes. Reasonable arguments
may be made in favor and against each of these points. Ultimately,
a realistic balance of the risks of the disease and risks of
treatment must be presented to patients and decisions must consider
individual tolerance for risk, while adhering to a number of basic
principles, including first do no harm. Level of Information:
Advanced
32. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana ^ MEET THE PROFESSOR:
WHAT IS NEW IN MS TREATMENT-THE BENEFITS IN EVERYDAY CLINICAL
PRACTICE Clinicians now have choices of a wide array of disease
modifying therapies primarily for relapsing forms of the disease.
The recent approval of ocrelizumab has added a broad new option for
treating progressive MS. It is now incumbent on neurologists to
remain well-informed about current and emerging evidence about
mechanisms of action, risk benefit profiles, as well as cost of
care. Dr. Comis lecture will enlighten delegates to the realities
and complexities of DMTs and MS. Level of Information: Basic,
Intermediate INTERNATIONAL ORGANIZATION OF MS NURSES (IOMSN) The
IOMSN is celebrating its 20th Anniversary. The dinner will feature
an update on IOMSN activities and programs for 2016-2017,
presentations of awards, and networking. After the presentations,
we will enjoy a night of music, dancing and socializing. Attendees
from the other dinners are invited to join IOMSN at the conclusion
of their respective dinners for some fun! INTERNATIONAL
ORGANIZATION OF MS REHABILITATION THERAPISTS (IOMSRT)
Rehabilitation professionals will share new strategies for managing
the ongoing challenges of multiple sclerosis as well as the latest
in MS rehabilitation research. MS MENTAL HEALTH PROFESSIONALS
(MS/MHP) Mental health professionals are a vital part of the MS
team. Social workers, psychologists, and psychiatrists will dine
together and strengthen their important network. MS COALITION The
MS Coalition is a group of nine MS organizations which serves as a
collaborative network to improve the quality of life for those
living with MS. The primary objectives of the MS Coalition are to
educate, advocate and provide resources and services for those
affected by MS. The MS Coalition dinner will feature a robust
presentation on the collective work of the Coalition in the past
year and the areas of focus for the future. MS PROFESSIONALS IN
TRAINING (MS-PIT) The Multiple Sclerosis Professionals in Training
Special Interest Group (MS-PiT) gathers specialists from neurology,
neuro-immunology, rehabilitation, nursing, and mental health who
are interested in or are entering into the field of multiple
sclerosis. The dinner will feature Dr. Randy Schapiro, Pat Kennedy,
Nurse Practitioner, and Brian Hutchinson, Physical Therapist. Each
speaker will share their personal journey in multiple sclerosis.
FUNDAMENTALS OF MS CARE: A CASE-BASED APPROACH TO DISEASE
MANAGEMENT 2017 Part I of Fundamentals offers a multidisciplinary
approach in the diagnosis and management of multiple sclerosis
(MS). The history of MS will offer participants an insight into the
disease and the changes that have led to improved approaches to
management. A comprehensive overview of MS will be presented to
include epidemiology, immunology, pathophysiology, current
diagnostic criteria, natural history, and clinical course,
including presentations on relapsing forms of MS and the challenges
in managing primary progressive MS. Disease management options will
be discussed to include current treatments and acute relapse
management. Pharmacologic and non-pharmacologic approaches used to
impact the disease will be examined. Faculty will offer discussions
on the role of MRI in differential diagnosis, MS management, and
identifying disease progression. This program will examine
neuromyelitis optica spectrum disease. Psychosocial implications
and the needs of patients dealing with chronic illness will be
included. An added session this year will include issues related to
women with MS. At the end of this program, the participant will be
able to discuss how MS is diagnosed, the benefits of comprehensive
care, current treatment options, the differences in managing MS
based on phenotype, the similarities and differences of MS and
neuromyelitis optica, and issues specific to women. Level of
Information: Basic, Intermediate FUNDAMENTALS OF MS CARE: A
CASE-BASED APPROACH TO SYMPTOM MANAGEMENT 2017 Part II of
Fundamentals offers a multidisciplinary approach to managing the
most common symptoms of MS. The benefits of integrative medicine
and a comprehensive approach to symptom management will be
examined. Discussions will provide an understanding into
pharmacologic and non- pharmacologic interventions used to improve
function and provide an optimal quality of life for individuals
living with MS. Topics will include managing sleep disorders, gait
dysfunction, sexual dysfunction, pain and sensory deficits, bowel
and bladder dysfunction, symptoms effecting activities of daily
living, including fatigue, depression, and cognitive function. The
importance of including health maintenance and wellness concepts in
the overall plan of care is discussed. At the end of this program,
participants will be able to discuss the importance of integrative
and comprehensive care, and define one pharmacologic and one
non-pharmacologic intervention used in managing four of the most
common symptoms experienced by multiple sclerosis patients. Level
of Information: Basic, Intermediate
33. 352017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana ^ CURRENT
TOPICS AND TRENDS IN MS REHABILITATION Rehabilitation is an
essential and necessary component in the comprehensive care of an
individual with MS at all stages of the disease. The Rehabilitation
Track programming will investigate up-to-date information on issues
relevant to the overall rehab care of persons with MS. Information
will be presented on new and emerging rehabilitation research as
well as clinical advances and treatment approaches of interest to
MS rehab professionals. Level of Information: Intermediate,
Advanced CORE CONCEPTS FOR THE MS NURSE: INTERNATIONAL CASE BASED
PERSPECTIVES The role of the nurse in MS care has grown in
importance and scope over the past 27 years, particularly around
disease control and comprehensive symptom management. MS nurses
throughout the world have been challenged to keep pace with the
evolution of the dynamic field of care. Country specific health
care systems are changing to meet demands of rising health care
costs, and this is a major challenge and often a barrier to optimum
care. The MS nurse continues to be at the forefront of designing
innovative ways to meet changing needs in the areas of disease
modifying treatments, symptom management, advocacy, and education.
The ultimate nursing goal, no matter where you practice in the
world, is to strive for patient centered care and autonomy. This
session will focus on key issues facing MS nurses today and will
present an international perspective from four faculty
participants. It will include the presentation of a selection of
patient issues and feature case presentations structured to promote
interactive audience participation. The faculty would like to
encourage our international MS Nurse participants to attend and
share in the discussion of country specific best practices. Level:
Intermediate WHITAKER TRACK The CMSC is proud to honor Dr. John
Whitakers memory by presenting the Whitaker Research Track each
year as part of its Annual Meeting. This project of the CMSC
includes the work of emerging scientists alongside MS experts in
clinical care and research. Students, post-doctoral fellows, and
young investigators are encouraged to submit abstracts of their
work for presentation during the Whitaker Track. Their work will
complement the presentations of their more seasoned colleagues.
Their interaction and discussions will be a valuable learning
experience. Level of Information: Intermediate, Advanced Clinical
Courses CLINICAL COURSE 1 MJ FOR MS?AN MS HEALTH PROFESSIONALS
GUIDE TO CANNABIS-PART 1 There is an increasing trend for marijuana
legalization for MS and other medical conditions, and there are
thousands of publications related to the safety and effectiveness
of marijuana. However, many MS health professionals may have no
education or training in marijuana and it may be difficult for
them, as well as people with MS, to obtain objective and practical
information in this area. As a result, clinicians and people with
MS may currently be making important decisions about marijuana use
without the basic facts that are necessary to determine if
marijuana is a reasonable treatment option. This two-part course
aims to provide an introduction to marijuana as well as specific
scientific and clinical information that is relevant to MS health
professionals. Part I will provide basic information, including
history, botany, and pharmacology. This section will also provide
detailed information about marijuana that is in a format similar to
that of the Prescribing Information (PI) and Patient Package Insert
(PPI) for medications, such as indications and usage, dosage and
administration, contraindications, warnings and precautions,
adverse reactions, and drug interactions. The ethical and
appropriate translation of this information into clinical practice
will be discussed. Part II of the course will provide detailed
information about the psychiatric and psychological aspects of
marijuana, including addiction, psychosis, and efficacy for
psychiatric conditions. This section will also address cognition
and functional brain changes in MS. The course will conclude with a
panel in which the three speakers will discuss specific clinical
scenarios. Level of Information: Basic, Intermediate, Advanced
CLINCIAL COURSE 2 REVIEW OF PHARMACOLOGY CONCEPTS PART 1: THE
EVOLUTION OF DISEASE MODIFYING THERAPIES The landscape of disease
modifying therapies (DMT) for Multiple Sclerosis (MS) has changed
significantly since 1993 when the first agent, interferon beta-1b,
was approved. Part 1 of this session will discuss the evolution of
therapies in regard to pharmacology, monitoring parameters and
risk/benefits of specific DMTs. Presentation of patient cases will
allow the attendee to gain real world experience in DMT selection
based on patient parameters. In Part 2 of the session, we will
examine common symptoms that develop in patients with MS (eg;
fatigue, cognitive complications, ambulatory issues, bladder
control and vaccinations). Available therapeutic options will be
discussed. The use of patient cases will develop clinical tools for
selection of appropriate pharmacologic treatments and patient
counseling. Level of Information: Intermediate
34. 2017 Annual Meeting of the Consortium of Multiple Sclerosis
Centers May 24-27 U New Orleans, Louisiana 36 ^ CLINICAL COURSE 3
MODELS OF REHABILITATION CARE The delivery of rehabilitation care
is changing dramatically from fee for service to a model of pay for
performance. Alternative Care Organizations (ACO) are forming all
over the country, often comprised of physician groups working
together to provide quality health care for their patients. In
addition, patient-centered medical homes (PCMH) are developing to
improve access to care as well as increase care coordination and
quality while reducing costs. This seminar will discuss the
integration of MS rehabilitation within a PCMH and ACO. Level of
Information: Basic, Intermediate CLINICAL COURSE 4 BEHAVIORAL
MEDICINE: LIFELINE FOR MS Behavioral medicine is an important and
necessary component in the interdisciplinary treatment of MS
patients. Evidence shows that when implemented early, behavioral
health services can improve the MS patients overall health, and
skills learned can assist them throughout their life. Patients and
family members often find the disease life-altering, as hopes,
dreams, and goals for the future may drastically change.
Individuals and family members react in a number of different ways,
including: grief, anxiety, anger, depression, fear, numbness,
denial, hopelessness, and suicidality. In addition to these
reactions to the stress of a life-altering illness, MS also affects
brain pathways in a way that predisposes individuals to develop
psychiatric illness and cognitive dysfunction. Lesions may be
neurologically silent and yet have profound effects on behavior,
mood, and cognition. This program will cover the early
incorporation of behavioral medicine into a neurology practice;
important psychological factors associated with MS, biological
underpinnings of behavioral illness in MS, and treatment of
behavioral health conditions in MS. The presenting team will be
integrated in experience from different medical settings and
specialties. Level of Information: Intermediate CLINICAL COURSES 5
THE FOUNDATION OF MS NURSING: BUILDING YOUR PRACTICE-PART I Nurses
play a unique role and remain a key member of the comprehensive
team model. The diverse and complex roles can present challenges to
the early career track nurses. This program will offer practical
tips for MS Nursing from the Canadian and US perspective. Part I
will present approaches to managing your practice and educating
your MS patients. We will touch on team member roles,
communication, time management and aspects of clinical care and
follow up. The program will offer general guidelines for MS
education for the newly diagnosed, relapse/ symptom management and
in the use of DMTs. Part II will offer approaches to managing
challenges and growing as a MS nurse. Topics will include advocacy,
dealing with the difficult issues of progressive disease/mental
health and access to care. We will discuss ways to further our
professional growth and how to sustain ourselves. We will provide
information for ongoing education opportunities, the use of
networking and strategies to take care of ourselves. Upon
completion of this session, attendees will: 1. Propose strategies
to set up practices to support components of nursing practice 2.
Develop strategies to assist patients to manage issues that impede
self-management 3. Identify general principles/guidelines for MS
education 4. Adapt resources to promote ongoing professional growth
Level of Information: Basic CLINICAL COURSE 6 CMSC MRI GUIDELINES:
A 2017 UPDATE MRI is essential for the early and accurate diagnosis
of Multiple Sclerosis. Standardized MRI protocols are required for
the monitoring of clinically silent disease activity as well as
safety. This interactive session will: Describe the recommended MRI
protocols Highlight typical imaging features of MS lesions and
discuss red flags Discuss the use and safety of gadolinium based
contrast agents (GBCA) Discuss the role of brain, spinal cord and
orbital MRI in establishing an early diagnosis How to use routine
brain MRI to monitor for clinically silent disease activity and PML
(progressive multifocal leukoencephalopathy) surveillance Discuss
the risk of misdiagnosis and how to re-evaluate the diagnosis of
MS
35. 372017 Annual Meeting of the Consortium of Multiple
Sclerosis Centers May 24-27 U New Orleans, Louisiana ^ Key points
that will be discussed include: GBCA remain essential in the
diagnostic evaluation of a patient suspected of having MS to
demonstrate newly active inflammatory lesions. Patient
characteristics that may necessitate the use of GBCA in routine
monitoring include: 1) worrisome clinical disease activity, 2) less
than two years on disease modifying therapies (DMT), 3) unexpected
clinical decline, 4) facilitates in selection of DMT, 5) large T2
lesion load making it excessively difficult to detect new T2
lesions. Emerging MRI sequences that demonstrate the central vein
sign (CVS) may improve specificity in challenging diagnostic cases.
DWI sequences have little usefulness in the initial diagnostic
evaluation, but are valuable in monitoring when there is concern
for PML or when age 40 and vascular disease risk factors are
present. The detection of spinal cord lesions remains invaluable in
the diagnostic workup. Sagittal 3D FLAIR of the brain may include
adequate coverage of the upper cervical spine to detect lesions. A
single cervical spinal cord exam that extends to T4 would detect
approximately 95% of spinal cord lesions. The rate of misdiagnoses
is high. Approaches to re-assessment of the original diagnosis are
described. Patients on DMT should have a new brain MRI within 3-6
months of starting to establish a new baseline for future
comparisons (DMT efficacy baseline). Some patients will also
require a new baseline MRI prior to switching (DMT safety baseline)
to ensure there is no pre-existing evidence of PML if previously on
a DMT associated with PML. Patients with continued stability on DMT
or with progressive disease require less frequent imaging. Level of
Information: Intermediate, Advanced CLINICAL COURSE 7 HOW TO
PERFORM THE EDSS The EDSS is the most widely used tool for the
assessment of disability in multiple sclerosis. However, the
performance and scoring of the EDSS is not straightforward. This
presentation will review the scale in detail. It will discuss the
scoring of the individual components and the overall scale by means
of clinical scenarios and an audience participation system for
immediate self-assessment and feedback. Some useful tools to aid in
this task will be presented and will be available for future use by
the participants. Familiarity with performance of the neurological
examination is assumed. Learning Objectives: 1. To describe the
structure and uses of the EDSS 2. To assign Functional Systems
Scores (FSS) to the various components of the neurological
examination 3. To calculate the EDSS from the FSS data Level of
Information: Basic, Intermediate CLINICAL COURSE 8 BASIC IMMUNOLOGY
FOR THE NON-IMMUNOLOGIST The immune system is a complex and elegant
system that protects us from infection and in addition, prevents
autoimmunity. However, when internal and environmental factors
interact and disrupt normal immune function, immune mediated and
auto-immune conditions can occur. Over the past few decades, much
has been learned about the role of the immune system in multiple
sclerosis (MS) and how certain lifestyle choices may influence MS
pathogenesis and disease progression. This session, divided into
basic immunology for the non-immunologist and advanced immunology
for the non-immunologist, will first explore the normal immune
system function and what is currently believed to be involved with
the abnormal response that ultimately produces the pathology seen
in MS. Additionally, in Part 1, the proposed immunological
mechanism of action for the disease modifying therapies will be
discussed. In Part 2, the discussion will focus on how
environmental factors and lifestyle modifications may impact the
altered immune response in MS. Level of Information: Basic-Part I;
Intermediate-Part 2 CLINICAL COURSE 9 MJ FOR MS?AN MS HEALTH
PROFESSIONALS GUIDE TO CANNABIS-PART 2 See Clinical Course 1 for
description. CLINICAL COURSE 10 REVIEW OF PHARMACOLOGY CONCEPTS
PART 2: BEYOND THE DMTS See Clinical Course 2 for description.
CLINICAL COURSE 11 TRANSLATING THE LATEST MOTOR LEARNING EVIDENCE
INTO PRACTICE This session will review the latest evidence to
support motor learning following central nervous system damage.
Principles of experience-dependent neuroplasticity and ways to
translate the evidence into practice will be reviewed. This
practical information will be geared towards rehabilitation
professionals. Level of Information: Intermediate CLINICAL COURSE 6
CMSC MRI GUIDELINES: A 2017 UPDATE (CONTINUED)
